

Vincenzo Pasceri

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10926925/vincenzo-pasceri-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

7,326
citations

29
h-index

42
g-index

42
ext. papers

7,919
ext. citations

9.7
avg, IF

5.4
L-index

#	Paper	IF	Citations
40	Direct proinflammatory effect of C-reactive protein on human endothelial cells. <i>Circulation</i> , 2000 , 102, 2165-8	16.7	1539
39	Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. <i>Circulation</i> , 2001 , 103, 2531-4	16.7	684
38	Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. <i>Circulation</i> , 2005 , 111, 2099-106	16.7	552
37	Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. <i>Circulation</i> , 2006 , 114, 1455-61	16.7	493
36	Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. <i>Circulation</i> , 2000 , 101, 235-8	16.7	472
35	Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. <i>Circulation</i> , 2004 , 110, 674-8	16.7	386
34	Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1272-8	15.1	366
33	Association of virulent <i>Helicobacter pylori</i> strains with ischemic heart disease. <i>Circulation</i> , 1998 , 97, 1675-8	16.7	255
32	Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 558-65	15.1	240
31	Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. <i>New England Journal of Medicine</i> , 1996 , 334, 7-12	59.2	196
30	Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast induced nephropathy] trial. <i>American Journal of Cardiology</i> , 2011 , 108, 1-7	3	157
29	C-reactive protein: linking inflammation to cardiovascular complications. <i>Circulation</i> , 2001 , 104, 974-5	16.7	157
28	Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. <i>Circulation</i> , 2005 , 111, 70-5	16.7	150
27	Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. <i>American Journal of Cardiology</i> , 1999 , 84, 854-6, A8	3	137
26	Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. <i>Circulation</i> , 2011 , 123, 1622-32	16.7	131
25	Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2008 , 101, 279-85	3	112
24	Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. <i>American Heart Journal</i> , 2007 , 153, 749-54	4.9	98

23	Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 552-9	15.1	97
22	Protection From Procedural Myocardial Injury by Atorvastatin Is Associated With Lower Levels of Adhesion Molecules After Percutaneous Coronary Intervention: Results From the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) Substudy. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1550-1555	15.1	94
21	Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 550-7	15.1	86
20	Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). <i>American Journal of Cardiology</i> , 2011 , 107, 207-213	3	83
19	Protection From Procedural Myocardial Injury by Atorvastatin Is Associated With Lower Levels of Adhesion Molecules After Percutaneous Coronary Intervention: Results From the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) Substudy. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1550-1555	15.1	83
18	High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized trial. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 771-9	15.1	75
17	Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 62-6	15.1	75
16	Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. <i>American Journal of Cardiology</i> , 2007 , 99, 1421-4	3	55
15	Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. <i>American Heart Journal</i> , 2006 , 151, 1215-22	4.9	51
14	Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). <i>American Journal of Cardiology</i> , 2010 , 110, 178-81	3	47
13	Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. <i>European Heart Journal</i> , 2010 , 31, 1337-43	9.5	33
12	A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. <i>American Heart Journal</i> , 2012 , 163, 1019-23	4.9	29
11	Relation between myocardial infarction site and pain location in Q-wave acute myocardial infarction. <i>American Journal of Cardiology</i> , 1995 , 75, 224-7	3	23
10	Statin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials. <i>Europace</i> , 2015 , 17, 855-63	3.9	20
9	Ischaemic preconditioning. <i>Lancet, The</i> , 1996 , 348, 204	4.0	13
8	Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 413-20	5.1	8
7	Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris. <i>American Journal of Cardiology</i> , 2006 , 98, 1461-3	3	8
6	Prevention of myocardial damage during coronary intervention. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2006 , 6, 77-83	1.1	6

5	Is there an antigenic mimicry between arteriosclerotic lesions and H. pylori antigens?. <i>Clinical Biochemistry</i> , 2000 , 33, 419-21	3.5	5
4	Risk Factors for Ischemic Heart Disease. <i>Reviews on Recent Clinical Trials</i> , 2019 , 14, 86-94	1.2	4
3	Response to Letters Regarding Article, Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) Study <i>Circulation</i> , 2007 , 115	16.7	2
2	Pretreatment with different loading doses of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) SELECT substudy. <i>Journal of Cardiovascular Medicine</i> , 2011 , 12, 151-6	1.9	1
1	Statins and percutaneous coronary intervention. <i>European Heart Journal</i> , 2005 , 26, 417; author reply 417-8	9.5	